JPRN-jRCT2080220723未知3 期
Confirmatory Study of OPC-12759 Ophthalmic Suspension in Dry Eye Patients
Otsuka Pharmaceuticals Co., Ltd.0 个研究点目标入组 180 人开始时间: 2009年4月22日最近更新:
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable(—)
- 性别
- All
入选标准
- •1. Out patient;
- •2. Subjective complaint of dry eye that has been present for minimum 20 months;
- •3. Ocular discomfort severity is moderate to severe;
- •4. Corneal-conjunctival damage is moderate to severe;
- •5. Unanesthetized Schirmer's test score of 5mm/5minutes or less;
- •6. Best corrected visual acuity of 0.2 or better in both eyes.
排除标准
- •1. Presence of anterior segment disease or disorder other than that associated with keratocojunctivitis sicca;
- •2. Ocular hypertension or glaucoma patients with ophthalmic solution;
- •3. Anticipated use of any topically-instilled ocular medications or patients who cannot discontinue the use during the study;
- •4. Anticipated use of contact lens during the study;
- •5. Patients with punctal plug;
- •6. Any history of ocular surgery within 12 months;
- •7. Female patients who are pregnant, possibly pregnant or breast feeding;
- •8. Known hypersensitivity to any component of the study drug or procedual medications;
- •9. Receipt of any investigational product within 4 months.
研究者
相似试验
未知
2 期
Exploratory study of OPC-12759 Ophthalmic SuspensioJPRN-jRCT2080221666Otsuka Pharmaceuticals Co., Ltd.100
未知
2 期
ate phase 2 study of OPC-12759 ophthalmic suspensioDry eyeJPRN-jRCT2080220394Otsuka Pharmaceutical Co., Ltd.
已完成
3 期
Confirmatory Study of OPC-12759 Ophthalmic SuspensionDry Eye SyndromesNCT00885079Otsuka Pharmaceutical Co., Ltd.188
未知
2 期
Dose-response study of OPC-12759 ophthalmic suspensioDry eyeJPRN-jRCT2080220040Otsuka Pharmaceutical Co., Ltd.
未知
3 期
ong Term Administration Study of OPC-12759 Ophthalmic SuspensioDry eye syndromesJPRN-jRCT2080220651Otsuka Pharmaceuticals Co., Ltd.153
